



Progress on Seasonal and Pandemic Influenza Vaccines

Guest Editors:

Prof. Emanuele Montomoli

Department of Molecular and
Developmental Medicine,
Università degli Studi di Siena,
Siena, Italy

Dr. Claudia Maria Trombetta

Department of Molecular and
Developmental Medicine,
University of Siena, Banchi di
Sotto, 55, 53100 Siena, SI, Italy

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editors

Dear Colleagues,

Vaccination is the most effective method of controlling seasonal influenza infections and preventing possible pandemic events. To date, three different classes of influenza vaccines have been licensed: inactivated, live attenuated and recombinant haemagglutinin vaccines. Most of the current influenza vaccines are still produced and/or isolated in hen's eggs; however, several novel platforms and technologies are being developed for the production of the next-generation vaccines.

This special issue focuses on recent progress on seasonal and pandemic influenza vaccines. The goal is to provide an overview of different types of influenza vaccine, new technologies and platforms under development for the next-generation vaccines.

This special issue invites contribution to these topics.

Prof. Emanuele Montomoli

Dr. Claudia Trombetta

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com